Septic Shock Treatment
Saving Lives, One Sepsis Treatment at a Time

Extracorporeal Blood Purification

Polymeric adsorbents for selective removal of bacterial endotoxins and cytokines.

Extracorporeal treatment in sepsis and multiple organ failure.

Safe and efficient method of critical patients stabilisation.

Efferon LPS

Next-generation extracorporeal blood adsorber, non-pyrogenic, gamma-sterilized, single-use medical device.

Selective adsorption of lipopolysaccharides and non-selective adsorption of cytokines, myoglobin, cellular debris, endogenous and exogenous toxic substances.

Indications

Sepsis of verified or suspected gram-negative aetiology, including septic shock.
Elevated levels of endotoxin in blood, critical endotoxemia.
Elevated levels of cytokines in blood, “cytokine storm” syndrome.

Efferon Rollup (10 x 15 cm) (10 x 7 cm) (7 x 10 cm) (5 x 10 cm) (4.5 x 10 cm)

Intended Use

Efferon is intended for extracorporeal blood purification via hemoperfusion in extracorporeal circuit. It can be used in direct hemoperfusion mode or in combination with RRT, ECMO and CPB.

Inflammatory mediators and endotoxin are removed from patients’ circulation. Timely administration improves vital functions and hinders progression of multiple organ failure in sepsis patients.

Lipopolysaccharide Adsorption at Septic Shock (LASSO) – Multicenter Randomised Clinical Study

Study Design: Patients with abdominal sepsis, complicated with septic shock, were randomly divided in two subgroups. Patients in intervention subgroup were subjected to first Efferon® LPS hemoperfusions in <12 hours since onset of septic shock and second Efferon® LPS hemoperfusion in 24 hours since start of the first one. Median duration of hemoperfusions were 5.5 hours. Patients in control group received standard of care treatment without extracorporeal removal of endotoxin or inflammatory mediators.

Study Conclusions: Efferon® LPS hemoperfusion yielded significant improvements of vital functions and survival rate in patients with septic shock.

Hemodynamics: increase of mean arterial blood pressure accompanied with decreased requirements to vasopressor and inotropic drugs (starting in 24 hours); shorter duration of septic shock among surviving patients (57 hours in Efferon® LPS vs 101 hours in control group); septic shock successfully resolved in 68% patients in Efferon® LPS group vs 40% in control group.
Respiratory function: shorter duration of invasive mechanical ventilation in surviving patients (2.6 days in Efferon® LPS vs 4.8 days in control group) higher chance of successful weaning from invasive mechanical ventilation (57% in Efferon® LPS vs 29% in control group) increase of PaO2/FiO2 oxygenation index (starting in 24 hours).
Renal function: lower serum creatinine (starting in 72 hours); shorter duration of renal replacement therapy.
Multiple Organ Failure Syndrome: lower SOFA score in Efferon® LPS hemoperfusion group (starting in 24 hours)
Inflammatory biomarkers: Efferon® LPS hemoperfusion decreased levels of abnormally elevated serum procalcitonin, C-reactive protein, interleukin-6, leukocytes and neutrophils count. 75% patients responded with decrease of endotoxin levels in blood.

Polymeric Adsorbent Efferon® LPS.

Mode of Action:

Multimodal adsorbent selectively binds two dissimilar therapeutic targets – bacterial endotoxins (PAMP molecules) and excessive cytokines (DAMP molecules).
Cytokines are bound by intrinsic porosity of polymeric scaffold.
Endotoxin is bound due to interaction with surface-immobilised LPS-selective ligand.